Zoetis Inc. Q3 2025 Earnings Recap

ZTS Q3 2025 November 6, 2025

Get alerts when ZTS reports next quarter

Zoetis delivered solid third-quarter results with a 4% revenue increase and a 9% rise in adjusted net income, showcasing resilience through a diverse product portfolio despite facing macroeconomic headwinds.

Earnings Per Share Beat

$1.70 vs $1.62 est.

+4.9% surprise

Revenue Miss

2400000000 vs 2409981227 est.

-0.4% surprise

Market Reaction

1-Day -0.77%

5-Day -0.31%

30-Day +5.61%

See ZTS alongside your other holdings

Add to your portfolio — free

Key Takeaways

Organic operational revenue growth of 6% in the International segment, with U.S. growth at 3% excluding the MFA divestiture.
Companion Animal revenue rose 2%, while Livestock revenue surged 10% driven by strong market demand.
The Simparica franchise saw 7% growth, supported by international momentum and recent approvals enhancing market reach.
A decline of 11% in osteoarthritis franchise sales indicates challenges, with focused strategies in place for recovery.
Upcoming product launches, including Lenivia and Portela, expected to reinforce Zoetis' leadership in chronic pain management.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ZTS on AllInvestView.

Next Q1 2026